

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

Natasha Kekre,¹ Haesook T. Kim,² Gita Thanarajasingam,³ Philippe Armand,⁴ Joseph H. Antin,⁴ Corey Cutler,⁴ Sarah Nikiforow,⁴ Vincent T. Ho,⁴ John Koreth,⁴ Edwin P. Alyea,⁴ and Robert J. Soiffer⁴

¹Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; ²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; ³Division of Hematology, Mayo Clinic, Rochester, MN; and ⁴Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.129650
Manuscript received on April 23, 2015. Manuscript accepted on June 16, 2015.
Correspondence: rsoiffer@partners.org

Supplemental Table. Patients undergoing IS taper alone versus Chemotherapy/Radiation for relapse after HCT.

Characteristic (N, %)	Chemotherapy or Radiation (N=340)	IS taper alone (N=123)	p-value
Age at HCT, median (range)	54 (19, 74)	58 (21, 71)	0.001
Patient gender			
Male	190 (55.9)	83 (67.5)	0.025
Female	150 (44.1)	40 (32.5)	
Diagnosis			
AML	131 (38.5)	70 (56.9)	0.0005
CLL/SLL/PLL	11 (3.2)	5 (4.1)	
CML	9 (2.6)	0	
HD	16 (4.7)	7 (5.7)	
MM/PCD	33 (9.7)	3 (2.4)	
ALL	36 (10.6)	2 (1.6)	
Other Leukemia	2 (0.6)	0	
MDS	41 (12.1)	18 (14.6)	
MPD	7 (2.1)	6 (4.9)	
Mixed MDS/MPD	5 (1.5)	1 (0.8)	
NHL	49 (14.4)	11 (8.9)	
HLA type (at A, B, DRB1)			
Matched unrelated	155 (45.6)	67 (54.5)	0.09
Matched related	146 (42.9)	37 (30.1)	
Mismatched unrelated	36 (10.6)	18 (14.6)	
Mismatched related	3 (0.9)	1 (0.8)	
Conditioning Intensity			
Myeloablative	101 (29.7)	22 (17.9)	0.01
Non-myeloablative	239 (70.3)	101 (82.1)	
Graft Source			
BM	13 (3.8)	6 (4.9)	0.12
PBSC	313 (92.1)	110 (89.4)	
BM & PBSC	0	2 (1.6)	
Umbilical Cord Blood	14 (4.1)	5 (4.1)	
GVHD prophylaxis			
Tacrolimus/Sirolimus/Methotrexate	155 (45.6)	56 (45.5)	0.79
Tacrolimus/Methotrexate	85 (25.0)	28 (22.8)	
Tacrolimus/Sirolimus	70 (20.6)	26 (21.1)	
Tacrolimus/Other	16 (4.7)	9 (7.3)	
T-cell depletion	3 (0.9)	0	
MMF/Other	11 (3.2)	4 (3.3)	